Predicting Bioactivity of PLK1 Inhibitor as Anti-Cancer Agent using Multilayer Perceptron Optimized by Simulated Annealing

Authors: Moechtar, Farhan Reypialfarizi, Kurniawan, Isman

Source: 2024 International Conference on Computer, Control, Informatics and its Applications (IC3INA) Computer, Control, Informatics and its Applications (IC3INA), 2024 International Conference on. :309-314 Oct, 2024

Relation: 2024 International Conference on Computer, Control, Informatics and its Applications (IC3INA)

Predictive Model of PLK1 Inhibitor Bioactivity as Anti-Cancer by Using Cuckoo Search-Ensemble Method

Authors: Fadhilah, Daffa Maulana, Kurniawan, Isman

Source: 2024 8th International Conference on Information Technology, Information Systems and Electrical Engineering (ICITISEE) Information Technology, Information Systems and Electrical Engineering (ICITISEE), 2024 8th International Conference on. :310-315 Aug, 2024

Relation: 2024 8th International Conference on Information Technology, Information Systems and Electrical Engineering (ICITISEE)

Centrobin serves as a safeguard to guide timely centriole maturation during the cell cycle

Authors: Dohyong Lee, Sungjin Ryu, Ji Hwa Hea, Globinna Kim, In-Jeoung Baek, Young Hoon Sung, Kunsoo Rhee

Source: Scientific Reports, Vol 15, Iss 1, Pp 1-15 (2025)

Subject Terms: Centrobin, Centriole, Distal appendage, Centriole maturation, Cell cycle, Plk1, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/3cdb7874ef694c1181ba5d804749f7b6

Broussoflavonol B induces S-phase arrest and apoptosis in pancreatic cancer cells by modulating the cell cycle checkpoint through inhibition of the AURKA/PLK1 pathway

Authors: HyokChol Choe, Zhen Wang, Jianhua Huang, Yutong Yang, Zhihao Zhao, HyonSu Jo, HyonU Pak, Tanveer Ali, Kaiyue Ding, Junnan Ma, Lingzhi Li, Dong Shang, Lin Zhang

Source: Cancer Cell International, Vol 25, Iss 1, Pp 1-22 (2025)

Subject Terms: AURKA, PLK1, Cell cycle checkpoint, Pancreatic cancer, Prenylated flavonoid, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cytology, QH573-671

File Description: electronic resource

Relation: https://doaj.org/toc/1475-2867

Access URL: https://doaj.org/article/1a0b01f424b64c0db5d6289c7f7dbdc5

Interference with CHD1L inhibits the malignant progression and enhances cisplatin sensitivity of ovarian cancer cells by binding PLK1

Authors: Kun Qiao, Yuanxiazi Guan, Wenjing Xing

Source: Journal of Ovarian Research, Vol 18, Iss 1, Pp 1-15 (2025)

Subject Terms: Ovarian cancer, CHD1L, PLK1, Proliferation, Apoptosis, Cell cycle arrest, Gynecology and obstetrics, RG1-991

File Description: electronic resource

Relation: https://doaj.org/toc/1757-2215

Access URL: https://doaj.org/article/fb5faa465d354826ae23358d55638a9b

The multi-target mechanism of action of Selaginella doederleinii Hieron in the treatment of nasopharyngeal carcinoma: a network pharmacology and multi-omics analysis

Authors: Huaguo Liang, Caifu Fang, Meng Qiu

Source: Scientific Reports, Vol 15, Iss 1, Pp 1-15 (2025)

Subject Terms: Selaginella doederleinii Hieron, Nasopharyngeal carcinoma, Network pharmacology, Molecular dynamics simulation, MAPK14, PLK1, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/7344ddff10384340a4df3649cf968579

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Authors: Sookhee Pae, Anna S. Sedukhina, Runa Sugiyama, Sarah J. Atanacio, Tatsuru Ohara, Masato Ishii, Kimino Minagawa, Romaan Akichjev, Fumie Go, Zayan Chandankeri, Zoran M. M. Janjetic, Eri Sato, Ayako Yamaura, Rei Meguro, Kishore Palanisamy, Ichiro Maeda, Osamu Takeuchi, Nao Suzuki, Kazuo Yudo, Juan A. Bernal, Ko Sato

Source: Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)

Subject Terms: PLK1, Overexpression, Cancer, Homologous recombination, PARP inhibition, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/3b34724f4cc6440fb543884b483ae34f

The effect of deuterated PLK1 inhibitor on its safety and efficacy in vivo

Authors: Tingyan Zhang, Xiaobing Deng, Haoping Jin, Zhengshu Peng, Yi-Ching Hsueh, Chunming Zhang, Gang Niu, Jianfei Yang

Source: Frontiers in Oncology, Vol 15 (2025)

Subject Terms: small molecule inhibitor, deuterated compound, PLK1, PK/PD, safety, efficacy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2025.1510052/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/23799589b5b34323a46e94a97d8af881

Dehydrodiisoeugenol targets the PLK1-p53 axis to inhibit breast cancer cell cycle

Authors: Lin Li, Yifan Zheng, Yongxia Yang, Senlin Shi, Shangjie Liu, Keying Huang, Luonan Qiu, Rongxin Zhang, Wenbin Huang, Yin Leng

Source: Frontiers in Pharmacology, Vol 16 (2025)

Subject Terms: breast cancer, dehydrodiisoeugenol, cell cycle, PLK1, P53, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2025.1545498/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/3658915361df41aebb63e30ff47dbd8a

Inflammatory damage caused by Echovirus 30 in the suckling mouse brain and HMC3 cells

Authors: Jichen Li, Yanjun Zong, Tiantian Sun, Ying Liu, Rui Wang, Jianfang Zhou, Qiang Sun, Yong Zhang

Source: Virology Journal, Vol 21, Iss 1, Pp 1-10 (2024)

Subject Terms: Echovirus 30, HMC3 cells, Inflammatory response, PLK1, Infectious and parasitic diseases, RC109-216

File Description: electronic resource

Relation: https://doaj.org/toc/1743-422X

Access URL: https://doaj.org/article/6664df3c18924fb595f40c103dae29db

Cancer Prevention with Molecular Target Therapies 4.0

Contributors: Paleari, Laura

Subject Terms: RNA-binding protein 3 (RBMS3), carcinogenesis, cancer prevention, target discovery, target therapy, epithelial–mesenchymal transition (EMT), Myc, kinases, PLK1, Aurora-A, Aurora-B, GSK-3, PKA, PIM, BRD4, kinase inhibitors, living donor liver transplantation, hepatocellular carcinoma, graft-to-recipient weight ratio, graft size, tumor recurrence, CAFs primary culture, CAF markers, patient-specific aggressive CAFs, post-surgery event, drug resistance, endometrial cancers, endothelial adhesion, biomechanics, mechanobiology, fluid shear stress, brain metastasis, biomarkers, gastric cancer, DNA-based markers, chemokines, MMPs, TIMPs, novel biomarker, pancreatic cancer, KRAS, KRAS inhibitors, KRAS-dependency, resistance, escaping, endometrial cancer, fertility preservation, molecular characterization, reproductive outcome, immune checkpoint inhibitor, head and neck cancers, head and neck squamous cell carcinoma, neutrophil extracellular traps, Th17, Treg, differentiation, colorectal cancer, evolution, HTLV-1, adult T-cell leukemia, viral oncogenesis, Tax, HBZ, apoptosis, Theatre studies, Oncology, Music

File Description: application/octet-stream

Access URL: https://directory.doabooks.org/handle/20.500.12854/152685
https://mdpi.com/books/pdfview/book/9805

Natural Compounds Applications in Drug Discovery and Development

Contributors: Bora, Alina, Crisan, Luminita

Subject Terms: red clover, extraction methods, biological activity, HPLC, phytochemical profile, antimicrobial activity, oxidative stress reduction, anti-inflammatory activity, ultrasound-assisted extraction, innovative extraction methods, betulinic acid−triazole derivatives, antiproliferative, cytotoxicity, melanoma, lung carcinoma, colorectal adenocarcinoma, Olea ferruginea, Oleaceae, ferruginan, anti-inflammatory, anti-diabetic, molecular docking, natural compound, anticancer, breast cancer, caspase-3, Janus kinase1/STAT3, STITCH, ADMET, docking, Mikania, methyl-3,5-di-O-caffeoyl quinate, cyclooxygenase, human neutrophil elastase, lipoxygenase, vitamin E derivatives, α-tocopheryloxyacetic acid (α-TEA), α-tocopheryl succinate (α-TS), cancer, mitocans, apoptosis, anti-tubercular, anti-cancer, drug repurposing, PLK1, pyrrolyl benzohydrazide derivative, DPP-4, pharmacophore screening, ADMETox, DFT, MLP, natural products, triazole derivatives, betulin, colorectal cancer, betulinic acid, betulinic acid derivatives, liposomal formulation, Medicine and Nursing, Surgery

File Description: application/octet-stream

Access URL: https://directory.doabooks.org/handle/20.500.12854/152834
https://mdpi.com/books/pdfview/book/10245

Kinase Inhibitor for Cancer Therapy

Contributors: Musumeci, Francesca

Subject Terms: JAK, synthesis, kinase inhibitory activity, pharmacological uses, binding mode/interactions, choline kinase, lipid metabolism, cisplatin, lung tumors, combinatorial chemotherapy, glioblastoma, Src, pyrazolo [3,4-d]pyrimidine scaffold, EGFR, multiple myeloma, tyrosine kinase, treatment, ibrutinib, gastric cancer, kinase inhibitor, ALK, targeted therapy, JNK3, fragment, saturation transfer difference NMR, X-ray crystallography, breast cancer, nanomedicine, PI3K?, poloxamers, polymeric nanoparticles, TPGS, zanubrutinib, anthracycline, drug resistance, aldo-keto reductase 1C3, ABC drug efflux transporter, Hsp90 inhibitor, co-chaperone, heterocycle molecules, anticancer agents, heat shock proteins, ER stress, PERK, UPR, kinase, inhibitor, cancer, diabetes, small molecule, structure–activity-relationship (SAR), MCL, ROR1, small molecules, apoptosis, AKT1, kinase inhibitors, acute myeloid leukemia, rare disease, molecular modeling, molecular docking, similarity search, MD simulation, computer-aided drug discovery, cutaneous T-cell lymphoma, TWIST1, erufosine, curcumin, synergy, nanotechnology, 3D tissue culture, 3D tumor model, tumor spheroids, drug screening, preclinical study, tyrosine kinase inhibitors, innate immunity, thyroid cancer, tumor-associated macrophages, cytokines, c-Src/Abl dual inhibitors, pyrazolo[3,4-d]pyrimidines, ADME, antiproliferative activity, childhood cancer, kinases, chemical inhibitors, clinical trials, dasatinib, CML, HIV-1, CMV, HIV functional cure, memory-like NK cells, T cells, anti-aging, senolytic, NSCLC, KAN0441571C, erlotinib, TTP, rigosertib, ON-01910.Na, cancer therapy, kinase allosteric inhibition, Plk1, Ras, JNK, PI3K/Akt, microtubule-destabilizing agents, stress-signaling pathways, aptamer, MNK1, therapeutic target, non-small cell lung cancer, antitumor, 4,5,6,7-tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine (DMAT) derivatives, protein kinase CK2, protein kinase PIM-1, dual protein kinase inhibitors, antitumor activity, autophagy, hepatocellular carcinoma, EGFR/PI3K/AKT/mTOR signaling, animal models, Mathematics and Science, Biology, life sciences, Molecular biology

File Description: application/octet-stream

Access URL: https://directory.doabooks.org/handle/20.500.12854/139351
https://mdpi.com/books/pdfview/book/9349

Fine-tuning probes for fluorescence polarization binding assays of bivalent ligands against polo-like kinase 1 using full-length protein

Authors: Tsuji, Kohei ^{a, b, ⁎}, Tamamura, Hirokazu ^a, Burke, Terrence R. ^b

Source: In Bioorganic & Medicinal Chemistry 1 March 2025 119

PLK1 phosphorylates WRN at replication forks

Authors: Wang, Lei ¹, He, Daheng ², Li, Qianjin ¹, Orren, David ^{1, 2}, Wang, Chi ^{2, 3}, Liu, Jinpeng ^{2, 3}, Li, Zhiguo ^{1, 2}, Liu, Xiaoqi ^{1, 2, ∗}

Source: In The Journal of Pharmacology and Experimental Therapeutics February 2025 392(2)

Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinoma

Authors: Kim, Da-Eun, Oh, Hyun-Ji, Kim, Hyun-Jin, Kim, Yeo-Bin, Kim, Seung-Tae, Yim, Hyungshin ^⁎

Source: In Biomedicine & Pharmacotherapy January 2025 182

PLK1 inhibition impairs erythroid differentiation

Authors: Peijun Jia, Yan Li, Lulu Duan, Jingxin Zhang, Yuanlin Xu, Huan Zhang, Chenghui Wang, Yaqian Gong, Ying Zhang, Longzhen Zhao, Yumin Huang, Shijie Zhang

Source: Frontiers in Cell and Developmental Biology, Vol 12 (2024)

Subject Terms: plk1, erythropoiesis, anemia, apoptosis, cell cycle, Biology (General), QH301-705.5

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fcell.2024.1516704/full; https://doaj.org/toc/2296-634X

Access URL: https://doaj.org/article/b27398a3262f4c3d8e98f0d054110555

Discovery of novel dihydropteridone derivatives as orally bioavailable PLK1 inhibitors with reduced hERG inhibitory activity for acute myeloid leukemia treatment

Authors: Hou, Yunlei ^a, Li, Shuang ^a, Ren, Le ^a, Zhang, Long ^a, Zhang, Na ^a, Miao, Ruifeng ^a, Huang, Qi ^a, Li, Zhiwei ^c, Hu, Changliang ^d, Xi, Zhiguo ^d, Tong, Minghui ^d, Gong, Ping ^a, Zhao, Yanfang ^a, Liu, Yajing ^{a, ⁎}, Liu, Jiuyu ^{b, ⁎⁎}

Source: In European Journal of Medicinal Chemistry 5 May 2025 289

Proteolysis targeting chimera of BI-2536 induces potent dual degradation of PLK1 and BET proteins

Authors: Song, Shiwei, Yang, Wanrong, Tai, Wanyi ^⁎

Source: In Bioorganic & Medicinal Chemistry 1 April 2025 120

FBXO45 levels regulated ferroptosis renal tubular epithelial cells in a model of diabetic nephropathy by PLK1

Authors: Zhu Bingming, Hu Yongxuan, Wu Ruishan, Yu Quan, Wen Wangrong

Source: Open Medicine, Vol 19, Iss 1, Pp 2107-18 (2024)

Subject Terms: fbxo45, diabetes nephropathy, plk1, Medicine

File Description: electronic resource

Relation: https://doaj.org/toc/2391-5463

Access URL: https://doaj.org/article/5bd1ac75080840979704ebb553bb8e8f